Top 5 Defensive Stocks To Buy For 2014

The Hidden Dangers of Defensive Stocks Source: Flickr

If recent market action has you thinking about using defensive stocks as a way to protect your portfolio against downside risk, you might want to think again.

Defensive stocks can provide a measure of protection in a down market … but not if the reason for the broader-market weakness is concern about Federal Reserve rate hikes.

Here�� why: Investors have poured cash into higher-yielding segments of the stock market, since they’re the only option at a time of low yields for bonds. As a result, defensive investments — including dividend stocks and low-volatility market ETFs — now have a substantial amount of imbedded interest rate risk.

Top Industrial Disributor Stocks To Watch Right Now: Ambit Biosciences Corp (AMBI)

Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Quizartinib

The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.

AC410

The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.

CSF1R Program

The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.

The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.

Advisors' Opinion:

• [By Wallace Witkowski]

  Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.

Top 5 Defensive Stocks To Buy For 2014: Great Plains Energy Inc (GXP)

Great Plains Energy Incorporated (Great Plains Energy), incorporated on February 26, 2001, is a public utility holding company. The Company does not own or operate any assets other than the stock of its subsidiaries. Great Plains Energy�� wholly owned direct subsidiaries with operations or active subsidiaries includes Kansas City Power & Light Company (KCP&L), and KCP&L Greater Missouri Operations Company (GMO). The Company is engaged in the business segment of electric utility. The electric utility segment consists of KCP&L, a regulated utility, and GMO�� regulated utility operations, which include its Missouri Public Service and St. Joseph Light & Power (L&P) divisions. Electric utility serves approximately 825,300 customers located in western Missouri and eastern Kansas.

KCP&L is an integrated, regulated electric utility that provides electricity to customers in the states of Missouri and Kansas. KCP&L has one active wholly owned subsidiary, Kansas City Power & Light Receivables Company (Receivables Company). GMO is an integrated, regulated electric utility that provides electricity to customers in the state of Missouri. GMO also provides regulated steam service to certain customers in the St. Joseph, Missouri area. GMO wholly owns MPS Merchant Services, Inc. (MPS Merchant), which has certain long-term natural gas contracts remaining from its former non-regulated trading operations.

Customers include approximately 726,100 residences, 96,600 commercial firms, and 2,600 industrials, municipalities and other electric utilities. During the year ended December 31, 2012, electric utility�� retail revenues averaged approximately 90% of its total operating revenues. Wholesale firm power, bulk power sales and miscellaneous electric revenues accounted for the remainder of electric utility�� revenues. During 2012, electric utility�� total electric revenues were 100% of Great Plains Energy�� revenues. During 2012, electric utility�� net income accounted for approximately! 108%, of Great Plains Energy�� income from continuing operations, respectively.

Advisors' Opinion:

• [By Justin Loiseau]

  Reeling in rates
  Great Plains Energy (NYSE: GXP  ) shares are up 18.3% in the past year, a sign that something's going right for this Missouri/Kansas utility company. Fiscal 2013 EPS bumped up 8%, but the real gains came from regulation risk reduction. After filing for rate increases in early 2012, Great Plains got the green light from regulators to boost its 2013 prices. On the unregulated front, the utility generates 83% of its electricity from coal and 14% from nuclear power, a (recently revealed) welcome relief from natural gas' rapidly rising prices.

• [By Justin Loiseau]

  As coal prices regain their competitive edge, investors should watch TECO Energy (NYSE: TE  ) , Great Plains Energy (NYSE: GXP  ) , and FirstEnergy (NYSE: FE  ) .

• [By Eric Volkman]

  Great Plains Energy (NYSE: GXP  ) is keeping its dividend as level as the geographical feature in its company name. The company will distribute $0.2175 per share of its common stock on June 20 to shareholders of record as of May 20.� This amount matches the company's previous two disbursements, the most recent of which was paid in March. Before that, Great Plains handed out $0.2125.

• [By David Dittman]

  Question: It�� not a popular name, but what are your thoughts on Great Plains Energy Inc (NYSE: GXP) with regard to dividend hikes and price?

  Answer: I have Great Plains Energy rated ��old��right now. But 100 percent of revenue is regulated–i.e., predictable and stable–and 2013 earnings growth was outstanding due to a resurgent regional economy.

Top 5 Defensive Stocks To Buy For 2014: Synovus Financial Corp.(SNV)

Synovus Financial Corp., a diversified financial services and bank holding company, provides commercial and retail banking, financial management, insurance, and mortgage services in Georgia, Alabama, South Carolina, Florida, and Tennessee. Its retail banking services include accepting customary types of demand and savings deposits; mortgage, installment, and other retail loans; investment and brokerage services; safe deposit services; automated banking services; automated fund transfers; Internet based banking services; and bank credit card services, including mastercard and visa services. The company?s commercial banking services comprise cash management and asset management services, capital markets services, and institutional trust services, as well as commercial, financial, and real estate loans. It also provides various other financial services, which include the portfolio management for fixed-income securities, investment banking, the execution of securities transac tions as a broker/dealer, and the provision of individual investment advice on equity and other securities; trust services; mortgage services; and financial planning services. Synovus Financial Corp. was founded in 1888 and is headquartered in Columbus, Georgia.

Advisors' Opinion:

• [By Rich Duprey]

  Southeastern regional bank�Synovus Financial (NYSE: SNV  ) �announced this morning�its second-quarter dividend of $0.01 per share, the same rate it's paid since 2009.

• [By Robert Eberhard]

  Much-maligned regional bank Synovus Financial (NYSE: SNV  ) reported first-quarter earnings this morning, and it pretty much went as expected. With consensus estimates pegging the Georgia bank at $0.02 earnings per share, Synovus didn't disappoint and met that number, and the stock has risen in trading today.

• [By Eric Volkman]

  Synovus (NYSE: SNV  ) is tapping the markets for a fresh round of financing. The company announced that it will float just under 59.9 million shares of its common stock in an underwritten public offering priced at $3.09 per share. The estimated net proceeds of the issue are estimated at $175 million. This cash pile, in conjunction with a planned preferred stock issue and dividends from a subsidiary, will be used to repay nearly $1 billion in TARP funds the government provided to Synovus.

Top 5 Defensive Stocks To Buy For 2014: Resolute Energy Corporation(REN)

Resolute Energy Corporation, an independent oil and gas company, engages in the acquisition, exploration, exploitation, and development of oil and gas properties in the United States. It primarily holds interests in the Aneth Field properties that cover approximately 43,000 gross acres on the Navajo Reservation in southeast Utah. The company? producing properties are located in the Powder River Basin, Wyoming; the Bakken shale trend of the Williston Basin in North Dakota; and the Permian Basin of Texas It also owns exploration properties in the Permian Basin of Texas; and the Big Horn and Powder River Basins of Wyoming. As of December 31, 2011, the company had estimated net proved reserves of approximately 64.8 million equivalent barrels of oil. Resolute Energy Corporation is based in Denver, Colorado.

Advisors' Opinion:

• [By Garrett Cook]

  In trading on Wednesday, energy shares were relative leaders, up on the day by about 0.59 percent. Top gainers in the sector included Parker Drilling Co (NYSE: PKD), Alpha Natural Resources (NYSE: ANR), and Resolute Energy (NYSE: REN).